Skip to Content

Join the 'Keveyis' group to help and get support from people like you.

Keveyis News

FDA Approves Keveyis (dichlorphenamide) for Primary Hyperkalemic and Hypokalemic Periodic Paralysis

Posted 10 Aug 2015 by

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Aug. 10, 2015-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that the U.S. Food and Drug Administration (FDA) has approved Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis [1]. Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States [2]. “The approval of Keveyis demonstrates the importance of industry, scientific researchers, patient advocates and the FDA working together to identify and bring to market a treatment for primary periodic paralysis,” said Kal Sundaram, Chief Executive Officer of Taro. “Taro is proud of its commitment to this community, which has b ... Read more

Related support groups: Dichlorphenamide, Hyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis, Keveyis

Ask a Question

Further Information

Related Condition Support Groups

Hypokalemic Periodic Paralysis, Primary Periodic Paralysis, Hyperkalemic Periodic Paralysis

Keveyis Patient Information at